Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2015

Conditions
Bipolar I Disorder
Interventions
DRUG

Lithium treatment in combination with a SGA (Second Generation Antipsychotic)

"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."

DRUG

Placebo/Adjunctive SGA treatment

"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."

Trial Locations (1)

11004

The Zucker Hillside Hospital, North Shore-LIJ Health System, Glen Oaks

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Northwell Health

OTHER

NCT01495156 - Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania | Biotech Hunter | Biotech Hunter